MYC and cancer: Oncogenes such as BRAF and MYC, through multifaceted shaping of central carbon metabolism and mitochondrial activity, can dictate the propensity of cancer cells to rely on specific metabolic routes such as glycolysis and glutaminolysis, thus revealing susceptibilities to metabolic drugs (9–13).